{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273272","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.354919+00:00","generated_at":"2026-05-16T22:30:46.755102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cabaletta Bio Q3 2025 R&D expenses $39.8M; rese-cel BLA submission targeted for 2027","bullets":["R&D expenses of $39.8M in Q3 2025, up from $26.3M a year ago; cash $159.9M as of Sep 30, 2025.","Myositis registrational cohort (14 patients) set to begin enrollment by year-end 2025; BLA submission planned for 2027.","FDA alignment on registrational cohort designs for SSc and SLE trials expected by year-end 2025.","EMA granted PRIME designation for rese-cel in myositis; FDA granted RMAT for SLE/LN and Fast Track for gMG.","Steve Gavel appointed Chief Commercial Officer; led CARVYKTI launch at Legend Biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273272","json":"https://secwatch.observer/filing/0001193125-25-273272.json","markdown":"https://secwatch.observer/filing/0001193125-25-273272.md","text":"https://secwatch.observer/filing/0001193125-25-273272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/0001193125-25-273272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/caba-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:30:46.755102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}